Published in J Infect Dis on November 01, 1979
Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol (1994) 2.63
The meningococcus and mechanisms of pathogenicity. Microbiol Rev (1982) 2.39
Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992. Clin Diagn Lab Immunol (1995) 2.00
Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev (2006) 1.53
HmbR, a hemoglobin-binding outer membrane protein of Neisseria meningitidis, undergoes phase variation. J Bacteriol (1999) 1.40
Haemophilus influenzae type b conjugate vaccines. Immunology (2004) 1.37
Meningococcal lipopolysaccharides: virulence factor and potential vaccine component. Microbiol Rev (1993) 1.26
Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine. Infect Immun (1998) 1.25
Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol (2004) 1.22
Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine. Infect Immun (2003) 1.12
Molecular epidemiology of meningococcal disease in England and Wales 1975-1995, before the introduction of serogroup C conjugate vaccines. Microbiology (2008) 1.01
Measurement of the human immune response to meningococcal lipooligosaccharide antigens by using serum to inhibit monoclonal antibody binding to purified lipooligosaccharide. Infect Immun (1990) 1.00
Group C Neisseria meningitidis variant polysaccharide vaccines in children. Infect Immun (1981) 0.97
Recognition of serogroup A Neisseria meningitidis serotype antigens by human antisera. Infect Immun (1985) 0.91
Meningococcal conjugate vaccines: optimizing global impact. Infect Drug Resist (2011) 0.89
Murine immune response to Neisseria meningitidis group C capsular polysaccharide: analysis of monoclonal antibodies generated in response to a thymus-independent antigen and a thymus-dependent toxoid conjugate vaccine. Infect Immun (2000) 0.89
Priming for immunologic memory in adults by meningococcal group C conjugate vaccination. Clin Vaccine Immunol (2006) 0.85
Review of meningococcal vaccines with updates on immunization in adults. Hum Vaccin Immunother (2014) 0.83
Functional activities and immunoglobulin variable regions of human and murine monoclonal antibodies specific for the P1.7 PorA protein loop of Neisseria meningitidis. Infect Immun (2000) 0.82
Epidemiologic characteristics of an outbreak of serogroup C meningococcal disease and the public health response. Public Health Rep (1995) 0.82
Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine. Infect Immun (1998) 0.82
Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice. Infect Immun (2003) 0.82
Surface plasmon resonance analysis of antipolysaccharide antibody specificity: responses to meningococcal group C conjugate vaccines and bacteria. Infect Immun (2004) 0.82
From genes to vaccine: A breakthrough in the prevention of meningococcal group B disease. Paediatr Child Health (2011) 0.80
Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine. Bull World Health Organ (1983) 0.80
Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children. Vaccine (2014) 0.78
Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study. Eur J Pediatr (2013) 0.78
Reactivity and immunogenicity of bivalent (AC) and tetravalent (ACW135Y) meningococcal vaccines containing O-acetyl-negative or O-acetyl-positive group C polysaccharide. Infect Immun (1983) 0.77
Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccine. J Occup Med Toxicol (2013) 0.76
Statement on meningococcal vaccination for travellers. Committee to Advise on Tropical Medicine and Travel. CMAJ (1995) 0.75
Immune Responses in U.S. Military Personnel Who Received Meningococcal Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were Higher than in Personnel Who Received MenACWY Alone. Clin Vaccine Immunol (2016) 0.75
Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine. Clin Vaccine Immunol (2012) 0.75
Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med (1969) 13.87
Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr (1984) 9.61
Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med (1969) 9.01
Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med (1969) 6.17
Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict (1992) 5.02
Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med (1970) 4.90
Migration of lymphocytes and thymocytes in the rat. I. The route of migration from blood to spleen and lymph nodes. J Exp Med (1968) 4.55
Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis (1978) 4.00
Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med (1969) 3.96
Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J Infect Dis (1986) 2.81
Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man. J Infect Dis (1970) 2.71
Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ (1971) 2.64
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology (2012) 2.60
The pathology of the joint tissues and its clinical relevance in prosthesis failure. Clin Orthop Relat Res (1976) 2.46
Disseminated fusarial infection in the immunocompromised host. Rev Infect Dis (1989) 2.46
The serum bactericidal system: ultrastructural changes in Neisseria meningitidis exposed to normal rat serum. J Exp Med (1969) 2.32
Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr (1990) 2.28
2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy. Lancet (1997) 2.28
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length. Pediatrics (1989) 2.21
Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphtheria-pertussis-tetanus toxoids-polio vaccine. Pediatr Infect Dis J (1987) 2.20
Studies of thymocytopoiesis in rats and mice. I. Kinetics of appearance of thymocytes using a direct intrathymic adoptive transfer assay for thymocyte precursors. J Exp Med (1986) 2.20
Identification of an epidemic strain of group C Neisseria meningitidis by bactericidal serotyping. J Infect Dis (1971) 2.17
Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest (1975) 2.16
Results from the 1995 National College Health Risk Behavior Survey. J Am Coll Health (1997) 2.13
[Fumaric acid as therapeutic agent for multiple sclerosis]. Nervenarzt (2014) 1.97
Migration of lymphocytes and thymocytes in the rat. II. Circulation of lymphocytes and thymocytes from blood to lymph. Lab Invest (1968) 1.94
Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain (2001) 1.91
Etiology of acute childhood encephalitis at The Hospital for Sick Children, Toronto, 1994-1995. Clin Infect Dis (1998) 1.85
Thymocytopoiesis is maintained by blood-borne precursors throughout postnatal life. A study in parabiotic mice. J Immunol (1992) 1.84
Otitis media. Clinical observations, microbiology, and evaluation of therapy. Am J Dis Child (1968) 1.81
Immunogenicity of the group A and group C meningococcal polysaccharides in children. J Infect Dis (1972) 1.81
Survey of parents' attitudes to the recommended Haemophilus influenzae type b vaccine program. CMAJ (1987) 1.72
Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol (2006) 1.62
Potential mechanisms for failure to eradicate group A streptococci from the pharynx. Pediatrics (1999) 1.61
The importation of hematogenous precursors by the thymus is a gated phenomenon in normal adult mice. J Exp Med (2001) 1.61
Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia. J Antimicrob Chemother (1983) 1.60
Interrelationships of viral, mycoplasmal, and bacterial agents in uncomplicated pneumonia. Am Rev Respir Dis (1968) 1.58
Ontogeny of terminal deoxynucleotidyl transferase-positive cells in lymphohemopoietic tissues of rat and mouse. J Immunol (1979) 1.54
Immunoglobulin molecules on the surface of activated T lymphocytes in the rat. J Exp Med (1973) 1.53
Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics (1977) 1.50
Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am J Pathol (1993) 1.50
Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approaches. Acta Neurol Scand (2003) 1.49
The distribution of terminal deoxynucleotidyl transferase (TdT) among subsets of thymocytes in the rat. J Immunol (1976) 1.47
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients]. Nervenarzt (2010) 1.45
Anatomical distribution of T and B lymphocytes in the rat. Development of lymphocyte-specific antisera. J Exp Med (1973) 1.44
A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases. Clin Orthop Relat Res (1985) 1.42
Intravenous Immunoglobulins in MS. Int MS J (2005) 1.41
Treating HIV encephalopathy with antiretroviral therapy: a clinical case demonstrating the success of HAART. Clin Infect Dis (2004) 1.41
Tissue-specific cell-surface antigens in embryonic cells. J Cell Biol (1972) 1.41
Intracellular distribution of terminal deoxynucleotidyl transferase in rat bone marrow and thymus. Proc Natl Acad Sci U S A (1977) 1.38
Chronic recurrent multifocal osteomyelitis: a noninfectious inflammatory process. Pediatr Infect Dis J (1987) 1.37
The impact of an enteroviral RT-PCR assay on the diagnosis of aseptic meningitis and patient management. J Clin Virol (2002) 1.37
Recent thymic emigrants in the rat express a unique antigenic phenotype and undergo post-thymic maturation in peripheral lymphoid tissues. J Immunol (1993) 1.36
Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood (2000) 1.35
Giant axonal neuropathy. A clinically and morphologically distinct neurological disease. Arch Neurol (1974) 1.34
Immunogenicity of group A and group C meningococcal polysaccharides in human infants. J Infect Dis (1973) 1.33
Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol (1989) 1.31
A specific circulating antigen in hamsters infected with Schistosoma mansoni. Detection of antigen in serum and urine, and correlation between antigenic concentration and worm burden. Am J Trop Med Hyg (1969) 1.30
The sequelae of Haemophilus influenzae meningitis in school-age children. N Engl J Med (1990) 1.27
The Immunization Monitoring Program Active (IMPACT) prospective five year study of Canadian children hospitalized for chickenpox or an associated complication. Pediatr Infect Dis J (2000) 1.27
Demonstration of Thy-1 antigen on pluripotent hemopoietic stem cells in the rat. J Exp Med (1978) 1.26
Epidemiology of lead poisoning. A comparison between urban and rural children. JAMA (1973) 1.26
Analysis of rat hemopoietic cells on the fluorescence-activated cell sorter. I. Isolation of pluripotent hemopoietic stem cells and granulocyte-macrophage progenitor cells. J Exp Med (1980) 1.26
Investigations into sources of lead in the environment of urban children. Environ Res (1975) 1.24
Direct thymic involvement in anterior chamber-associated immune deviation: evidence for a nondeletional mechanism of centrally induced tolerance to extrathymic antigens in adult mice. J Immunol (1997) 1.20
Adenoviral pneumonia and its complications in infancy and childhood. J Can Assoc Radiol (1969) 1.20
Role of airborne lead in increased body burden of lead in Hartford children. Environ Health Perspect (1974) 1.20
Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatr Infect Dis (1985) 1.19
Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology (2004) 1.19
Microglial phagocytosis of apoptotic inflammatory T cells leads to down-regulation of microglial immune activation. J Immunol (2001) 1.18
Sequelae of acute bacterial meningitis in children treated for seven days. Pediatrics (1986) 1.17
Blood mononuclear cells induce regulatory NK T thymocytes in anterior chamber-associated immune deviation. J Leukoc Biol (2001) 1.16
Demonstration of terminal deoxynucleotidyl transferase in thymocytes by immunofluorescence. Proc Natl Acad Sci U S A (1977) 1.16
Fumaric Acid and its esters: an emerging treatment for multiple sclerosis. Curr Neuropharmacol (2009) 1.15
Diffusion of ions in myelinated nerve fibers. Biophys J (1979) 1.14
Immune Response of human infants of polysaccharide vaccines of group A and C Neisseria meningitidis. J Infect Dis (1977) 1.13
Induction of terminal deoxynucleotidyl transferase and Lyt antigens with thymosin: identification of multiple subsets of prothymocytes in mouse bone marrow and spleen. Proc Natl Acad Sci U S A (1981) 1.13
T-lymphocyte maturation: cell surface markers and immune function induced by T-lymphocyte cell-free products and thymosin polypeptides. Ann N Y Acad Sci (1979) 1.12
Administration of measles, mumps, and rubella virus vaccine (live) to egg-allergic children. JAMA (1990) 1.12
Epidemiologic study of 4684 hospital-acquired infections in pediatric patients. Pediatr Infect Dis J (1989) 1.12
Prevention of gram-positive sepsis in neonates weighing less than 1500 grams. J Pediatr (1994) 1.12
High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol (2001) 1.10